Sodium channel protein type 9 subunit alpha

BE0001143ProteinHumansSCN9A

Pore-forming subunit of Nav1.7, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes (PubMed:38381792, PubMed:40768348). It is acted on by 15 drugs in DrugBank.

Gene name
SCN9A
UniProtKB entry
Q15858Swiss-Prot
Cellular location
Cell membrane
Residues / weight
1,988 residues · 226,370 Da
Also known as
hNE-Na · NENA · Neuroendocrine sodium channel · Peripheral sodium channel 1 · PN1

Resolves to

Protein
UniProtQ15858UniProt nameSCN9A_HUMAN
Gene
HGNCHGNC:10597NCBI Gene6335GenBank758110GeneCardsSCN9A
Pharmacology
IUPHAR/GtoPdb584KEGGhsa:6335
Structure
PDB21TPPDB21TQPDB5EK0
Drugs

What you can answer from here — as of September 07, 2019

15DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
2Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
11GO termsFunction, process and component, as structured annotations
Sign in
4Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
55+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Sodium channel protein type 9 subunit alpha, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In